CORONAVIRUS

Reminder: COVID-19 vaccination with the AstraZeneca vaccine by the Occupational Health Department

In accordance with the recommendations issued by the French National Authority for Health (HAS) on February 2, 2021, the AstraZeneca vaccine can be used for vaccination against COVID-19. The physicians in the Occupational Health Department are now authorized to vaccinate STAFF WHO WISH TO BE VACCINATED as part of the national vaccination campaign.
 

  • The first vaccinations with the AstraZeneca vaccine by the Institut Pasteur Occupational Health Department began on March 10.

In accordance with national guidelines, priorities for these vaccination sessions are as follows:

  1. healthcare workers under the age of 65

  2. staff members aged 50 or over with underlying health conditions: complicated high blood pressure, a history of stroke or coronary artery disease, complicated diabetes, sleep apnea, etc. (see list of health conditions in French)

  3. laboratory staff handling SARS-CoV-2 (not covered by national guidelines). The General Directorate of Health has allocated 120 doses of the AstraZeneca vaccine for staff in this category who will be vaccinated regardless of age and underlying health conditions starting March 22

  • In practice

These three staff groups received an email from the Occupational Health Department with a Doodle link enabling them to make an appointment for vaccination provided they are eligible:
-    because of their health situation (see list of health conditions (in French) )
-    on the grounds of occupational exposure

  • In total: 220 appointments are available to you until April 2

The vaccination drive will then gradually be extended to all staff (depending on the available vaccine doses).

List of underlying health conditions that quality for priority vaccination :

•    cardiovascular conditions: complicated high blood pressure (with cardiac, renal and cerebrovascular complications), a history of stroke or coronary artery disease, heart surgery or advanced heart failure (NYHA III or IV);
•    diabetes that is poorly controlled or involves complications;
•   chronic respiratory disease that may lead to decompensation in the event of a viral infection: especially obstructive pulmonary disease, severe asthma, pulmonary fibrosis, sleep apnea and cystic fibrosis;
•    obesity (body mass index (BMI) ≥ 30 kg/m2);
•    progressive cancer being treated (excluding hormone therapy);
•    class B or C cirrhosis according to the Child-Pugh score;
•    congenital or acquired immunodeficiency;
•    major sickle cell disease or a history of splenectomy;
•    motor neuron disease, myasthenia gravis, multiple sclerosis, Parkinson's disease, cerebral palsy, tetraplegia or hemiplegia, a malignant primary brain tumor, progressive cerebellar ataxia;
•    cancer and hematological malignancies being treated with chemotherapy;
•    severe chronic kidney disease, including patients receiving dialysis;
•    solid organ transplant recipients;
•    allogeneic hematopoietic stem cell transplant recipients;
•    multiple chronic diseases with dysfunction of at least two organs;
•    specific rare diseases that represent a particular risk in the event of infection (list drawn up by rare disease healthcare bodies);
•    Down syndrome.

Print